HryASX disclosureRe prelims per above successful indication- But...

Hry

ASX disclosure

Re prelims per above successful indication- But no point inferring that results were not good sinply bcs mgt didn't say the C word.

Presumably hard for them to do so at this stage bcs ino

1) prelim
2) do these tests need to be extrapolated? Ie lets say it cleared 50% and reduced inflammation by 50% ... would it be 99 9% after 2 years, higher dosage, combined with some for of adjutant? Does it need to do much better than say 30 or 40% to be of value?

Per MM theres some specific areas of improvement that ino would see this stock commercialise in near term eg HAND (dinentia issue) and reduces inflammation easing burden of immune system.

Had a former colleague die over night after nearly beating leukaemia from a bacteria infection due to immunity being shot from chemo. 50's. Anecdotally special oncology drug was circa 250k

Doesnt need to be a 'cure' to get commercialised imo

So, whilst I appreciate that the prelims are not definitive. Any assumption without full scientific consideration wont deter me from this when management says new class of drug in same context as positive results.

Lets not forget ppl are on the cart drugs for life atm

DYOR